| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net revenue | 722,519 | 814,319 | 784,513 | 724,508 |
| Cost of goods sold | 402,406 | 517,129 | 510,539 | 438,255 |
| Gross profit | 320,113 | 297,190 | 273,974 | 286,253 |
| Affordable Medicines Segment-Operating Segments | 41,318 | NaN | NaN | NaN |
| Amneal Specialty Pharma Segment-Operating Segments | 34,691 | NaN | NaN | NaN |
| Av KARESegment-Operating Segments | 16,680 | NaN | NaN | NaN |
| Corporate Non Segment | 46,171 | NaN | NaN | NaN |
| Selling, general and administrative | 138,860 | 146,458 | 137,815 | 124,266 |
| Research and development | 38,383 | 34,819 | 63,352 | 47,964 |
| In-process research and development impairment charges | NaN | 0* | NaN | NaN |
| Intellectual property legal development expenses | 1,542 | 1,411 | 2,437 | 2,017 |
| Acquisition costs | 5,153 | NaN | NaN | NaN |
| Restructuring and other charges | 650 | 2,470 | 143 | 1,024 |
| Charges related to legal matters, net | -694 | 0* | 0 | 390 |
| Other operating income | 6,941 | 1 | 117 | 0 |
| Operating income (loss) | 141,772 | 112,033 | 70,344 | 111,372 |
| Interest expense, net | -53,361 | -56,237 | -62,814 | -65,101 |
| Foreign exchange (gain) loss, net | -7,800 | -1,437 | -3,431 | 8,256 |
| Gain on refinancing | -3,510 | 0 | -31,365 | NaN |
| Decrease (increase) in tax receivable agreement liability | 2,333 | -12,289 | 20,808 | -4,420 |
| Other income, net | 742 | 13,165 | 1,235 | 1,604 |
| Total other expense, net | -61,596 | -56,798 | -75,567 | -59,661 |
| Income before income taxes | 80,176 | 55,235 | -5,223 | 51,711 |
| Provision for income taxes | 2,176 | 5,662 | -23,355 | 16,101 |
| Net income | 78,000 | 49,573 | 18,132 | 35,610 |
| Less net income attributable to non-controlling interests | NaN | 55,876 | NaN | NaN |
| Net income (loss) attributable to amneal pharmaceuticals, inc | NaN | -6,303 | NaN | NaN |
| Basic EPS | 0.2 | -0.02 | 0.01 | 0.07 |
| Diluted EPS | 0.19 | -0.019 | 0.01 | 0.07 |
| Basic Average Shares | 316,023,000 | 314,507,000 | 314,168,000 | 313,739,000 |
| Diluted Average Shares | 328,933,000 | 328,142,000 | 324,754,000 | 322,363,000 |
Amneal Pharmaceuticals, Inc. (AMRX)
Amneal Pharmaceuticals, Inc. (AMRX)